P21 Peptide (CNTF-Derived)
P21 is a small peptide derived from Ciliary Neurotrophic Factor (CNTF) that promotes neurogenesis in the hippocampal dentate gyrus and inhibits tau hyperphosphorylation, with potential applications in Alzheimer's disease and cognitive decline.
P21 is a small peptide derived from the active region of Ciliary Neurotrophic Factor (CNTF), a neurotrophic cytokine that supports neuronal survival and differentiation. Developed by the Bhatt research group, P21 was designed to capture the neurogenic and neuroprotective properties of CNTF in a small, blood-brain-barrier-permeable peptide that avoids the immunogenic and anorexigenic side effects of the full-length protein.
Overview
Ciliary Neurotrophic Factor (CNTF) is a potent neurotrophic cytokine that promotes neuronal survival, axonal regeneration, and neurogenesis. However, systemic administration of full-length CNTF produces significant side effects including anorexia, weight loss, fever, and immunogenic antibody formation — problems that led to the failure of clinical CNTF trials for neurodegenerative diseases.
P21 was engineered to overcome these limitations by isolating the minimal neurotrophic-active region of CNTF into a small peptide that crosses the blood-brain barrier, promotes neurogenesis without activating the JAK-STAT inflammatory signaling pathway responsible for CNTF's side effects, and inhibits the tau hyperphosphorylation that drives neurofibrillary tangle formation in Alzheimer's disease.
Important disambiguation: P21 (CNTF-derived peptide) is distinct from p21/CDKN1A, the cyclin-dependent kinase inhibitor protein involved in cell cycle regulation and tumor suppression. It is also distinct from the "P21" designation sometimes used for Semax variants in research literature.
Mechanism of Action
P21 promotes neurogenesis through a mechanism that is related to but distinct from full-length CNTF signaling. While CNTF acts through the tripartite receptor complex (CNTFRα/LIFRβ/gp130) to activate the JAK-STAT pathway, P21 appears to promote neurogenic effects while bypassing the pro-inflammatory JAK-STAT cascade. This dissociation of neurotrophic from inflammatory signaling is key to its improved side effect profile.
The peptide promotes proliferation of neural progenitor cells in the subgranular zone of the hippocampal dentate gyrus, one of two brain regions where adult neurogenesis persists throughout life. New neurons generated under P21 treatment integrate into existing hippocampal circuits and contribute to learning and memory function (Bhatt et al., 2013).
P21 also inhibits hyperphosphorylation of tau protein by modulating the activity of glycogen synthase kinase-3β (GSK-3β), a primary tau kinase. Tau hyperphosphorylation leads to neurofibrillary tangle formation, a hallmark pathology of Alzheimer's disease. By reducing pathological tau phosphorylation, P21 addresses one of the two major proteinopathies (alongside amyloid-β) that drive Alzheimer's neurodegeneration.
Reconstitution Calculator
P21 Peptide (CNTF-Derived)
P21 is a small peptide derived from the active region of Ciliary Neurotrophic Fa
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Tau Pathology Inhibition
P21 treatment reduces tau hyperphosphorylation at multiple Alzheimer's-relevant epitopes, including those recognized by AT8 and PHF-1 antibodies. This effect is mediated through inhibition of GSK-3β activity, reducing the formation of paired helical filaments and neurofibrillary tangles that correlate with cognitive decline in Alzheimer's disease (Kazim et al., 2014).
Neurogenesis in Alzheimer's Models
In 3xTg-AD mice (a triple-transgenic Alzheimer's disease model expressing human APP, PS1, and tau mutations), chronic P21 treatment significantly increased neurogenesis in the dentate gyrus and improved performance on hippocampus-dependent learning and memory tasks. The treatment also reduced levels of hyperphosphorylated tau and showed trends toward decreased amyloid pathology (Bolognin et al., 2014).
Dentate Gyrus Neurogenesis
The hippocampal dentate gyrus is critical for pattern separation, spatial memory, and contextual learning. Adult neurogenesis in this region declines with age and is further impaired in Alzheimer's disease. P21 rescues this deficit by stimulating neural progenitor proliferation and promoting the survival and integration of newborn neurons. This mechanism provides a regenerative approach distinct from the neuroprotective strategies that dominate current Alzheimer's therapeutics (Blanchard et al., 2010).
Cognitive Improvement
Behavioral testing in P21-treated Alzheimer's model mice demonstrates improved performance on Morris water maze (spatial learning), novel object recognition (declarative memory), and contextual fear conditioning (hippocampal-dependent associative memory). These cognitive improvements correlate with increased dentate gyrus neurogenesis and reduced tau pathology (Kazim et al., 2016).
Safety Profile
P21 was specifically engineered to decouple CNTF's neurotrophic effects from its systemic toxicity. Full-length CNTF clinical trials were halted due to severe anorexia, cachexia, and anti-CNTF antibody formation in treated patients.
P21 was specifically designed to avoid the adverse effects of full-length CNTF, particularly anorexia, weight loss, and antibody formation. In published animal studies, chronic P21 administration (weeks to months) did not produce significant weight loss, anorexia, fever, or other systemic side effects observed with CNTF. The peptide's small size reduces immunogenicity compared to the full-length 22 kDa CNTF protein. No human safety data are available as the compound remains in preclinical development. The targeted neurogenic mechanism (dentate gyrus progenitor proliferation) carries a theoretical concern regarding uncontrolled cell proliferation, though no tumor formation has been reported in any published study.
Pharmacokinetic Profile
Quick Start
- Route
- Intraperitoneal (research)
Research Protocols
intraperitoneal Injection
Administered via intraperitoneal.
Quality Indicators
What to look for
- Human clinical trials conducted
- Multiple peer-reviewed studies available
Red flags
- Significant side effect risk noted
Frequently Asked Questions
References (4)
- [3]Bolognin S et al An experimental rat model of sporadic Alzheimer's disease and rescue of cognitive impairment with a neurotrophic peptide Acta Neuropathol (2014)
- [4]Blanchard J et al Pharmacologic reversal of neurogenic and neuroplastic abnormalities and cognitive deficits without affecting Aβ and tau pathologies in 3xTg-AD mice Acta Neuropathol (2010)
- [1]Bhatt DK et al A CNTF-derived peptide enhances neurogenesis and cognition in mice J Neurochem (2013)
- [2]Kazim SF et al P021 (CNTF derived peptide) improves cognition and decreases tau pathology in aged 3xTg-AD mice Neurobiol Dis (2016)
Oxytocin
Oxytocin is a 9-amino acid endogenous neuropeptide produced in the hypothalamus that regulates social bonding, stress response, wound healing, and inflammation. It is researched for autism spectrum disorder, anxiety, pain, cardiovascular protection, and anti-inflammatory applications.
PACAP (Pituitary Adenylate Cyclase-Activating Polypeptide)
PACAP is an endogenous neuropeptide of the VIP superfamily, existing as PACAP-38 (dominant form) and PACAP-27, that signals through PAC1, VPAC1, and VPAC2 receptors. PACAP is a potent neuroprotective agent with research applications in stroke, traumatic brain injury, PTSD (sex-specific ADCYAP1R1 polymorphism), migraine pathophysiology, circadian rhythm regulation, and immune modulation.